Maalox chewable pills 20 pcs
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Algeldrat + Magnesium hydroxide
Release form
Pills
Composition
1 tablet contains: Active substances: magnesium hydroxide 400 mg, algaldrat (AB form of hydrated aluminum oxide) 400 mg (equivalent to 200 mg of aluminum oxide), Excipients: starch with sucrose (sugar, confectionery), sorbitol, mannitol, magnesium stearate, peppermint flavoring , sodium saccharinate, sucrose.
Pharmacological effect
Antacid medication. Neutralizes free hydrochloric acid of gastric juice, without causing its secondary hypersecretion. Due to the increase in the pH of gastric juice when taking the drug Maalox decreases the peptic activity of gastric juice. The drug also has an adsorbing and enveloping effect, which reduces the effect of damaging factors on the mucous membrane of the esophagus and stomach.
Pharmacokinetics
Magnesium hydroxide and aluminum hydroxide are considered to be local antacids that are practically not absorbed when taken in recommended doses and, accordingly, do not have systemic effects.
Indications
Peptic ulcer of the stomach and duodenum in the acute phase. Acute gastroduodenitis. Chronic gastroduodenitis with normal or elevated secretory function in the acute phase. Hernia of the esophageal opening of the diaphragm. Reflux esophagitis. Dyspepsia (and their prevention) resulting from the use of certain drugs including NSAIDs, GCS). Discomfort or epigastric pain, heartburn with errors in diet, excessive use of coffee, alcohol, nicotine.
Contraindications
Severe renal dysfunction. Hypersensitivity to the drug.
Precautionary measures
On the part of the immune system: the frequency is unknown - hypersensitivity reactions, anaphylactic reactions. Allergic reactions: frequency is unknown - itching, urticaria, angioedema. On the part of the digestive system: infrequently - diarrhea, constipation. On the part of the metabolism: the frequency is unknown - hypermagnesemia, hyperaluminiemia, hypophosphatemia (with long-term treatment or taking in high doses, or when taken in standard doses with a low phosphate content in the diet), which can lead to increased bone resorption, hypercalciuria, osteomalacia.
Use during pregnancy and lactation
To date, no specific teratogenic effects have been identified with the use of Maalox during pregnancy, however, due to insufficient clinical experience with its use in pregnancy, prescribing is possible only if the potential benefit of therapy for the mother justifies the potential risk to the fetus. When using the drug in accordance with the dosing regimen, the absorption of combinations of aluminum hydroxide and magnesium salts in the mother’s body is limited, therefore Maalox is recognized to be compatible with breastfeeding. In preclinical studies in animals, there is no clear indication of the teratogenic effect in aluminum hydroxide and magnesium hydroxide.
Dosage and administration
Adults take 1-2 pills 3-4 times / day. 1-2 hours after meals and overnight. With reflux esophagitis, the drug is taken in a shorter period of time after meals. The duration of treatment should not exceed 2-3 months. For occasional use (for example, for discomfort after errors in the diet) 1-2 pills once.
Side effects
From the alimentary system -muscular system, Alzheimer's disease.
Overdose
Symptoms: diarrhea, abdominal pain and vomiting are possible. In patients at risk, taking high doses of the drug can cause or aggravate intestinal obstruction or intestinal obstruction. Treatment: aluminum and magnesium are excreted in the urine. Losses and forced diuresis are replenished. Patients with renal insufficiency need to undergo hemodialysis or peritoneal dialysis.
Interaction with other drugs
With simultaneous use with quinidine, it is possible to increase serum concentrations of quinidine and develop an overdose of quinidine. When taken simultaneously with the drug Maalox, the following drugs are absorbed from the gastrointestinal tract: histamine H2 receptor blockers, propranolol, atenolol, cefdinir, cefpodoxime, metoprolol, chloroquine, prostacyclin, diflunisal,digoxin, bisphosphonates, ethambutol, isoniazid, fluoroquinolones, sodium fluoride, corticosteroids (described for prednisolone and dexamethasone), indomethacin, ketoconazole, linkosamides, neuroleptics of phenothiazine derivatives, penicillamine, rovuvastatin, core salts, heart, heart, heart, heart, heart, heart, heart, heart, heart, heart, heart, heart, rastuvastatin, neuroleptics derived from phenothiazine, penicillamine, rovuvastatin, heart, heart, heart, heart, heart, heart, heart, heart, body, heart, heart, body, blood, body weight, body weight, body weight, body weight, body weight, body size In the case of a 2-hour interval between taking these drugs and Maalox and the 4-hour interval between taking fluoroquinolones and Maalox, in most cases this unwanted interaction can be avoided. When combined use of the drug Maalox with polystyrenesulfonate (kayeksalat) care should be taken because of the possible risk of reducing the efficiency of potassium binding resin and the development of metabolic alkalosis in patients with renal insufficiency (for aluminum hydroxide and magnesium hydroxide) and intestinal obstruction (for aluminum hydroxide). The combination of aluminum hydroxide with citrates may increase the plasma concentrations of aluminum, especially in patients with renal insufficiency.
special instructions
Aluminum hydroxide can cause constipation, an overdose of magnesium salts can lead to a weakening of intestinal peristalsis; in high-risk patients (patients with renal insufficiency, the elderly), taking high doses of the drug may cause or aggravate intestinal obstruction and intestinal obstruction. Aluminum hydroxide is poorly absorbed from the gastrointestinal tract, so in patients with normal renal function, systemic exposure occurs rarely. However, long-term treatment, use of the drug in excessively high doses, or use of the drug in usual doses against the background of reduced intake of phosphates from food can lead to phosphate deficiency (due to the binding of aluminum to phosphate), which is accompanied by increased bone resorption and hypercalciuria. osteomalacia. Patients at risk of developing phosphate deficiency or long-term use of the drug should be treated under medical supervision. If renal failure is impaired, plasma concentrations of magnesium and aluminum may increase. In these patients with long-term use of the drug Maalox in high doses may develop encephalopathy, dementia, microcytic anemia or worsening of osteomalacia caused by dialysis. If during treatment the symptoms of the gastrointestinal tract persist for more than 10 days or a worsening of the condition is observed, then the diagnosis should be clarified and treatment should be corrected.Observe the 2-hour interval between use of the drug Maalox and other drugs. Long-term use of the drug Maalox in renal failure should be avoided. Despite the fact that the drug is released without a prescription, before using the drug during pregnancy and lactation (breastfeeding), as well as in adolescents, it is recommended to consult with your doctor. Aluminum hydroxide with a low phosphate content in food can lead to the development of phosphorus deficiency in the body. Therefore, in its application, especially long-term, it is necessary to ensure adequate intake of phosphates from food. The drug is permeable to X-rays. When using the drug in patients with diabetes mellitus, the presence of sucrose in the composition of Maalox chewable pills should be taken into account. Impact on the ability to drive vehicles and control mechanisms: The drug does not affect the ability to drive vehicles and work with mechanisms.